Imunon posts Q3 2026 loss but reports progress on Phase 3 ovarian cancer trial

Imunon reported a net loss of $3.8 million ($0.64 per share) for the third quarter of 2026, wider than the $3.4 million loss a year earlier. Operating expenses fell to $3.4 million. The company said enrollment in its Phase 3 OVATION‑3 trial of IMNN‑001 is on schedule, targeting 50 % enrollment by the first quarter of 2028 and full enrollment by the first quarter of 2029. It also transferred its ThermoDox rights to VoxelDox, with the deal contingent on VoxelDox obtaining funding.

Imunon noted that cash of $4.0 million plus $5.0 million in restricted cash as of September 30 2026 provides liquidity to fund ongoing trial activities. The trial timeline, if met, could drive future revenue and affect the company’s valuation.

  • 1Net loss for Q3 2026 was $3.8 million, or $0.64 per basic and diluted share, compared with $3.4 million, or $1.16 per share, in Q3 2025.
  • 2Operating expenses for the quarter were $3.4 million.
  • 3Cash on hand was $4.0 million and restricted cash was $5.0 million as of September 30 2026.
  • 4Enrollment in the OVATION‑3 Phase 3 trial is expected to be completed by the first quarter of 2029, with 50 % of patients enrolled by the first quarter of 2028.
  • 5Imunon agreed to transfer its ThermoDox rights to VoxelDox, a transaction that will only close if VoxelDox secures funding.

Sources